“Forever Young” Stocks
The science is constantly evolving with new breakthroughs and discoveries being made all the time. Aging today is increasingly being characterized as a disease and everyone is trying to find the “cure” using innovative therapies and cutting-edge technologies, to simple yet effective lifestyle changes.
Investing in the longevity and health industry can be also a smart financial decision. As people live longer and the demand for solutions to age-related health issues increases, the market for companies specializing in longevity and health is expected to continue growing.
This market is driven by factors such as increasing life expectancy, rising awareness about the importance of healthy aging and advancements in technology and medicine.
Experts like Dr. Joe Dispenza, Dr. Peter Attia, Dr. Andrew Huberman, Dr. David Sinclair and many others like them, are pushing the boundaries of what we know about longevity and health. Through their work, they are making a difference in people’s lives and inspiring others to live their best life.
Whether you’re looking to improve your own health, support companies that are making a positive impact, or invest in the industry, the field of longevity and health is an exciting place to be.
Maximizing Your Life and Your Portfolio: Longevity Stocks to Invest In
Investors can take advantage of this growth by investing in companies that are leading the way in the longevity and health industry. These companies can range from biotechnology firms developing new treatments for age-related diseases, to genetic testing companies providing personalized health insights, to medical device companies improving minimally invasive surgical procedures as well as companies dealing with preventive medicine.
When investing in the longevity and health industry, it is important to consider factors such as a company’s financial performance, product pipeline and competitive landscape. As with any investment, it is also important to conduct thorough research.
Many of these companies are still privately owned but there are also well-established ones with a strong track record of financial performance making them an attractive option for investors in the stock market.
For instance, the iShares Biotechnology ETF is one that caught my attention. It tracks the performance of an index composed of U.S.-listed equities in the biotechnology sector.
Seasonal Chart of iShares Biotechnology ETF over the past 10 years
Source: Seasonax, click on the link http://tiny.cc/Seasonax-iSharesBiotech to open an interactive seasonal chart
Keep in mind that a seasonal chart depicts the average price pattern of a specific asset in the course of a calendar year, calculated over several years (unlike a standard price chart that simply shows prices over a specific time period). The horizontal axis depicts the time of the year, while the vertical axis shows the % change in the price (indexed to 100). The prices reflect end of day prices and do not include daily price fluctuations.
Looking at the seasonal chart above, time period from March 23 until August 5 over the last 10 years has been a quite favourable for this ETF. The performance rose on average by almost 13%. Moreover, since 2013 the pattern returns had a winning strike of 90%, meaning iShares biotechnology ETF generated gains in 9 out of the 10 years during the selected time period.
One of the biggest challenges facing this industry is Alzheimer’s disease, a devastating neurodegenerative condition that affects millions of people worldwide. As the world’s population ages, the number of people affected by Alzheimer’s is expected to rise significantly, making it a critical area of focus for the longevity industry.
Several companies listed on the stock exchange are actively working on developing treatments for Alzheimer’s disease from Biogen, Cassava Sciences to many more.
Another promising company that is at the forefront of the fight against Alzheimer’s disease and aging-related conditions is Germany-based biotech Evotec.
From a market entry perspective, investors who have invested their money from March onwards during the last 10 years have had a competitive advantage compared to others. This company brought on average almost 20% return for the time period from March 7 until August 13.
For the detailed statistics take a look at the interactive chart below.
Seasonal Chart of Evotec over the past 10 years
Source: Seasonax, for further analysis click on the link http://tiny.cc/Seasonax-Evotec
In addition to these biotech/pharmaceutical companies, other businesses in the longevity industry are also addressing Alzheimer’s disease. For example, technology companies like IBM are using artificial intelligence and machine learning to develop tools that can help diagnose and track the progression the disease.
Investing in companies that are improving people’s lives and addressing important health issues can not only be profitable, but also personally fulfilling. So, whether you are a seasoned investor or just starting out, consider exploring the opportunities in the longevity and health industry and make a positive impact with your investments.
When choosing the “right” ones, make use of Seasonax to identify best entry and exit points based on recurring patterns. By signing up for free to https://app.seasonax.com/signup, you will be able to scan for more than 25.000 instruments, including different sectors, stocks, (crypto)currencies, commodities, and indexes.
Remember, don’t just trade it, Seasonax it!
Co-Founder and Managing Partner of Seasonax
Tea Muratovic has worked in the financial industry for many years and has gained a strong financial background in the international market environment. Her strength lies in Capital Market Products & Asset Management. As the Founder of Seasonax (www.seasonax.com) and investment boutique Seasonax Capital (www.seasonax-capital.com) she has received several investment awards and been recognized by the industry experts for her achievements. Moreover, Muratovic is author of many articles that have been featured in industry relevant media (Institutional Money, Munich Stock Exchange, TalkMarkets, FundView, Bloomberg…).